As part of its new portfolio of online educational activities, the EBMT, with the special collaboration of Professor Christian Chabannon, is proud to offer a new CAR-T cell e-course for all members.
CAR-T cell and other Immune Effector Cell (IEC) based therapies share similarities with hematopoietic cell transplants, however are strikingly different in many aspects. Understanding the supply chain as well as key aspects of patient’s management, including risk mitigation plans, are paramount to ensuring the safety of treated patients and maximizing the efficacy of the medicinal products. EBMT has called on experts in the field to cover these different aspects, ranging from patient selection, evaluation, treatments and follow-up, to collection of the starting material by apheresis, reception, delivery and administration of the manufactured CAR-T cells to patients following lympho-depletion. We hope this will help you and your colleagues to reach the proper level of training to confidently care for your patients and their families.
- Dr. Jürgen Kuball, UMCU Utrecht, The Netherlands
- Christian Chabannon. Head & Qualified person. Centre de Thérapie Cellulaire. Institut Paoli-Calmettes. Comprehensive Cancer Centre. Professor of Medicine in Cell Biology. Aix-Marseille Université School of Medicine. Marseille. France
- María Estela Moreno Martínez. Clinical Pharmacist, BCOP. Hospital de la Santa Creu I Sant Pau, Barcelona
- Prof. Catherine Thieblemont. Head, Hemato-oncology – APHP, Saint-Louis Hospital – Paris. Paris University – Sorbonne Paris Cite. Scientific director of the Clinical Research Center – Saint-Louis hospital
- Prof. Dr. Peter Bader. Vice Director KKJM. Head; Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine. Hospital for Children and Adolescents. University Hospital Frankfurt
- Arnon Nagler, M.D., M.Sc. Vice-chair ALWP of the EBMT. Hematology Division, BMT and CBB. Chaim Sheba Medical Center, Tel Hashomer, Israel
- Nicolaus Kröger. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Ibrahim Yakoub-Agha, MD, PHD. Lille University Hospital. France
- Stephan Mielke. Head of Allogeneic Stem Cell Transplantation and Cell Therapy (CAST), K. Scientific Director of the Cancer Center, K. Professor of Hematology and Cellular Therapy, KI. Karolinska Institutet (KI) and University Hospital (K), Stockholm, Sweden. Professor of Medicine, Wuerzburg University Hospital, Germany
- Álvaro Urbano-Ispizua. Hospital Clínic Barcelona. University of Barcelona.
- Rose Ellard. Lecturer Practitioner, Royal Marsden Hospitals NHS Foundation Trust, London, UK. Nurse member, EBMT Cellular Therapy and Immunobiology Working Party
Evaluation and accreditation
After studying all the modules, there will be a quiz. The estimated time to do this course is eight hours.
We are pleased to announce that the e- course is accredited by the EBAH-CME credits system.
After the e-course, an updated attendance list will be uploaded to the EBAH-CME website. Only attendees who have obtained the CAR-T cell e-course diploma will be eligible to receive CME points.
If you don’t have an EBAH-CME account, we recommend you create one by clicking here.
If after 15 days following the event you do not have your EBAH-CME credits in your account, please contact the EBMT e-learning department at firstname.lastname@example.org.
This course is directed to all specialists involved in patient care when applying CAR-T cell treatment.
If you are a physician, this course will also help you to prepare for the CAR-T cell questions on the EBMT Exam.
This course is open to non-members for a limited time only.
How to register?
- To register click on the button below and complete the form.
- After, you will receive an email with a link to the platform and your login information.
The registration process is not automatic. It can take some days to process the information and receive the login information.
For any queries please contact: email@example.com